Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. VINGE ADVISES THE PRAMERICA GROUP IN CONNECTION WITH THE SALE OF ERIKSBERG SHOPPING CENTRE
Mandate

VINGE ADVISES THE PRAMERICA GROUP IN CONNECTION WITH THE SALE OF ERIKSBERG SHOPPING CENTRE

March 17, 2014

Vinge has advised TMW Pramerica Property Investment GmbH in connection with the sale of Fastighets AB Fogsvansen which owns and manages Eriksberg shopping centre in Gothenburg. The property is situated close to Linholmen in Hissingen and has a lettable area of 10 700 m2, all of which is currently leased to large tenants such AS Coop Extra and Systembolaget.

TMW Pramerica Immobilien GmbH is the European arm of Pramerica Real Estate Investors. The subsidiary, TMW Pramerica Property Investment GmbH acquired Eriksberg shopping centre in January 2005 on behalf of its fund, EuRetail. The Pramerica Group has owned the property for a decade.

Vinge’s team consisted of partner Magnus Pauli together with, among others, associates Mercedes Anderås, Natalie Bäck, Patrik Gargolinski, Lisa Hanicke, Daniel Lennartsson, Thelma Fredin and Frida Matsson as well as project assistant, Josefin Halldén. Partner Fredrik Vinge advised on financing issues and associate Maria Paijkull on environmental issues in relation to the transaction

Related

Vinge has advised Course Corrected VC on the establishment of Course Corrected VC Fund II

 Vinge has advised Course Corrected VC on the establishment and structuring of their second fund, Course Corrected VC Fund II (the “Fund”).
November 12, 2026

Vinge advises Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun

 Vinge is advising Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun from Dalafast. The acquisition comprises four properties with a total of 23,200 square metres of retail space, which together constitute Tallen’s largest retail area.
November 11, 2026

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

 On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026